SARS-CoV-2 and COVID-19 Research

The paper analyzes lung-draining lymph nodes from COVID-19 autopsies to identify distinct follicular Bcl6 reactivity subgroups and their associated immune and spatial transcriptomic profiles.

This paper uses advanced microscopy to show that SARS-CoV-2 attaches to and enters cells via heparan sulfate clusters, not ACE2, and that blocking HS binding inhibits viral infection.

This study identifies immune signatures associated with SARS-CoV-2 infection resolution in human lung tissues using a humanized mouse model.

This study compares self-amplifying and circular mRNA vaccines for SARS-CoV-2, finding that circular mRNA induces stronger memory T-cell responses and is stable at higher temperatures.

This study identifies DMBT1 as a co-receptor for SARS-CoV-2 infection and shows a SRCR-derived peptide can inhibit it.

This study uses synthetic coevolution to explore mutational trajectories between neutralizing antibodies and SARS-CoV-2 variants, revealing antagonistic and compensatory mutations.

This study investigates the ACE2 tropism of sarbecoviruses across 17 mammals using pseudovirus assays, structural analysis, and phylogenetics to identify genetic factors influencing host range.

This study develops a biophysical model to show how lipid binding and mutations affect Orf9b's conformational equilibrium and its interaction with Tom70, influencing interferon suppression.

This study identifies recombination events in HKU5-CoV-2 that affect the spike protein's receptor binding domain and furin cleavage site, potentially altering host tropism and infectivity.

This study shows phosphorylation of SARS-CoV-2 N protein toggles its condensate state between membrane-wetting and engulfment, revealing a regulatory mechanism for viral RNA replication and packaging.

This study assesses the neutralizing antibody titres against SARS-CoV-2 variants Delta and Beta post-Pfizer-BioNTech vaccination, finding significant reductions compared to wild-type virus.

This study identifies DAZAP2 as a pan-coronavirus restriction factor that inhibits viral entry and genomic replication, with physiological relevance confirmed in mouse models and human cells.

The paper identifies a new SARS-CoV-2 subgenomic RNA, ORF3a-E-sgRNA, which enhances viral replication and immune evasion by promoting translation and host protein interactions.

This study shows that aged Roborovski dwarf hamsters infected with SARS-CoV-2 develop severe lung inflammation, impaired respiratory function, and chronic pneumonia, which can be mitigated by antiviral treatment.

This paper develops an attenuated SARS-CoV-2 virus expressing nanoluciferase to identify and validate drug-resistant mutants to nirmatrelvir without using wild-type virus.

The paper identifies a mutation P812S in SARS-CoV-2 associated with immune evasion and upper airway adaptation, but reduced syncytia formation.

This study shows that the NSP4 T492I mutation increases SARS-CoV-2 mutation rates and accelerates the emergence of Omicron-like mutations.

This study shows that combining Nirmatrelvir with GRP78 inhibitors strongly reduces SARS-CoV-2 replication in vitro and in a hamster model.

This study presents a pre-fusion, open conformation of the SARS-CoV-2 S2 subunit and identifies antibodies that recognize it, providing insights into spike dynamics and potential vaccine targets.

This study shows angiotensin IV enhances SARS-CoV-2 entry at low concentrations but inhibits it at higher concentrations, suggesting a dual role in viral infection.

The paper experimentally separates the effects of amino acid substitutions on function and abundance for SARS-CoV-2 Mpro, revealing their distinct contributions to DMS outcomes.

This study identifies a humanized antibody XR10v48 that neutralizes SARS-CoV-2 variants and protects hamsters via nasal administration.

This study analyzes SARS-CoV-2 genomic data from Norfolk, UK, revealing high diversity and dynamic emergence of VOCs over 2.5 years.

This study compares replication capacity and nucleocapsid proteoforms across SARS-CoV-2 variants in human pulmonary cells, finding Omicron BA.1 has reduced replication and variant-specific proteoforms.

This study shows that the SARS-CoV-2 E protein's PDZ-binding motif enhances virulence by disrupting epithelial barriers and inflammation, but not neuroinvasion.

RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.

This study shows that the GPR4 antagonist NE-52-QQ57 improves survival, reduces inflammation, and lowers viral load in SARS-CoV-2-infected mice.

CoVerage predicts and characterizes SARS-CoV-2 Variants of Interest by analyzing lineage frequency dynamics and antigenic changes from GISAID data.

This study analyzes the structural and functional interactions of SARS-CoV-2 Nsp3 with the 5' UTR of the viral genome, identifying key domains involved in binding and translocation.